Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8943967 | Vaccine | 2018 | 8 Pages |
Abstract
Following PCV7/PCV13 introduction, rates of episodes caused by VT13 were substantially reduced in all 3 groups. However, differences in age distribution, serotype replacement and specific serotype decrease suggest different pathogenesis and host susceptibility between the 3 entities.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Shalom Ben-Shimol, Noga Givon-Lavi, Galia Grisaru-Soen, Orli Megged, David Greenberg, Ron Dagan, On behalf of the Israel Bacteremia and Meningitis Active Surveillance Group On behalf of the Israel Bacteremia and Meningitis Active Surveillance Group,